Fast Five Quiz: Radiation Therapy for Metastatic and Advanced Prostate Cancer

Evelyn S. Marienberg, MD


November 08, 2022

While moderate hypofractionation EBRT is the preferred regimen for low-volume metastatic disease, ultra-hypofractionation EBRT has acceptable efficacy and toxicity profiles, according to the NCCN guidelines. Conventional fractionation ERBT and SBRT have demonstrated acceptable efficacy and toxicity profiles for all NCCN risk groups. For regional disease, moderate hypofractionation EBRT and conventional EBRT may be appropriate. Brachytherapy monotherapy has acceptable efficacy and toxicity for very low, low, and favorable intermediate NCCN risk groups.

Learn more about radiation treatment of metastatic and advanced prostate cancer.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.